Abbott Laboratories $ABT Stock: Meeder Advisory Services Inc. Grows Position

Meeder Advisory Services Inc. lifted its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 18.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,118 shares of the healthcare product maker’s stock after acquiring an additional 6,608 shares during the period. Meeder Advisory Services Inc.’s holdings in Abbott Laboratories were worth $4,162,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. BlackRock Inc. boosted its stake in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp grew its position in Abbott Laboratories by 0.6% during the 3rd quarter. State Street Corp now owns 81,431,110 shares of the healthcare product maker’s stock worth $8,047,837,000 after purchasing an additional 504,876 shares during the last quarter. Bank of America Corp DE acquired a new position in Abbott Laboratories in the second quarter valued at $1,603,607,000. Deutsche Bank AG increased its stake in Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after purchasing an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc acquired a new position in Abbott Laboratories in the second quarter valued at $1,082,524,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their target price for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Leerink Partners upgraded Abbott Laboratories from a “market perform” rating to an “outperform” rating and set a $124.00 price target on the stock in a research report on Thursday. BTIG Research dropped their price target on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. UBS Group reduced their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, Weiss Ratings raised Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $119.04.

Get Our Latest Report on Abbott Laboratories

Abbott Laboratories Trading Down 0.9%

Shares of ABT stock opened at $102.96 on Friday. The business’s fifty day moving average price is $103.91 and its 200 day moving average price is $101.66. The firm has a market capitalization of $178.32 billion, a PE ratio of 38.42, a P/E/G ratio of 1.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $129.85.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. Abbott Laboratories’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.30 earnings per share. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 94.03%.

Insider Transactions at Abbott Laboratories

In related news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.46% of the company’s stock.

Top Abbott Laboratories Stories

Investors following ABT have been watching these stories:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
  • Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
  • Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.